Foghorn Therapeutics 

Foghorn Therapeutics 

Yahoo Finance • 14 days ago

Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset

The fair value estimate for Foghorn Therapeutics has been reset from US$6.00 to about US$4.17, reflecting a meaningful change in how the stock is currently modeled. This move lines up with recent Street commentary that factors in the FHD-9... Full story

Yahoo Finance • last month

Correction: Top Midday Decliners

(Corrects the first paragraph to indicate the federal court denied California's request to temporari PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Fall Late Afternoon

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index falling 1% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Top Midday Decliners

Corteva (CTVA) said Thursday that a federal court in California denied its request to temporarily bl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Foghorn Therapeutics, Inc. Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program Company to focus resources on wholly owned pipeline, including a Selective EP300 degrade... Full story

Yahoo Finance • 4 months ago

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s board as it advances den... Full story

Yahoo Finance • 4 months ago

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking ca... Full story

Yahoo Finance • 5 months ago

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Foghorn Therapeutics, Inc. WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting... Full story

Yahoo Finance • 8 months ago

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential in ER+ breast cancer tracking to IN... Full story

Yahoo Finance • last year

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story

Yahoo Finance • last year

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors - Selective CBP degrader is on track for... Full story

Yahoo Finance • last year

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story

Yahoo Finance • last year

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the biop... Full story

Yahoo Finance • 2 years ago

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Company to share new preclinical combination datafor FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional updates include new prec... Full story

Yahoo Finance • 2 years ago

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical data for FHD-909 in combination wit... Full story

Yahoo Finance • 2 years ago

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinic... Full story

Yahoo Finance • 2 years ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story

Yahoo Finance • 3 years ago

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

First patient dosed in FHD-286 combination study in AML; data expected in the second half of 2024Transitioned the BRM Selective inhibitor program to Loxo@Lilly Presented preclinical data demonstrating tumor growth inhibition and favorable... Full story

Yahoo Finance • 3 years ago

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story

Yahoo Finance • 3 years ago

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression,... Full story